• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Middle East African Journal of Ophthalmology >Update on Clinical Trials in Dry Age-related Macular Degeneration
【24h】

Update on Clinical Trials in Dry Age-related Macular Degeneration

机译：干燥年龄相关性黄斑变性的临床试验更新

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

This review article summarizes the most recent clinical trials for dry age-related macular degeneration (AMD), the most common cause of vision loss in the elderly in developed countries. A literature search through websites https://www.pubmed.org and https://www.clinicaltrials.gov/ , both accessed no later than November 04, 2015, was performed. We identified three Phase III clinical trials that were completed over the recent 5 years Age-Related Eye Disease Study 2 (AREDS2), implantable miniature telescope and tandospirone, and several other trials targeting a variety of mechanisms including, oxidative stress, complement inhibition, visual cycle inhibition, retinal and choroidal blood flow, stem cells, gene therapy, and visual rehabilitation. To date, none of the biologically oriented therapies have resulted in improved vision. Vision improvement was reported with an implantable mini telescope. Stem cells therapy holds a potential for vision improvement. The AREDS2 formulas did not add any further reduced risk of progression to advanced AMD, compared to the original AREDS formula. Several recently discovered pathogenetic mechanisms in dry AMD have enabled development of new treatment strategies, and several of these have been tested in recent clinical trials and are currently being tested in ongoing trials. The rapid development and understanding of pathogenesis holds promise for the future.
机译：这篇综述文章总结了干燥年龄相关性黄斑变性（AMD）的最新临床试验，这是发达国家老年人视力丧失的最常见原因。通过不迟于2015年11月4日访问的网站https://www.pubmed.org和https://www.clinicaltrials.gov/进行了文献检索。我们确定了在最近5年中完成的三项与年龄有关的眼病研究2（AREDS2），植入式微型望远镜和tandospirone的三项III期临床试验，以及针对多种机制的其他几项试验，这些机制包括氧化应激，补体抑制，视觉周期抑制，视网膜和脉络膜血流，干细胞，基因治疗和视觉康复。迄今为止，没有任何一种生物定向疗法能够改善视力。据报道，植入式微型望远镜改善了视力。干细胞疗法具有改善视力的潜力。与原始AREDS公式相比，AREDS2公式并没有进一步降低进展为晚期AMD的风险。干燥的AMD中最近发现的几种致病机制已促成新治疗策略的开发，其中一些已在最近的临床试验中进行了测试，目前正在进行中。发病机理的迅速发展和理解为未来带来了希望。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号